MilatuzuMab

Product NameMilatuzuMab
CAS899796-83-9
MF
MW0
EINECS
MOL FileMol File

Chemical Properties

form	Liquid
color	Colorless to light yellow

Usage And Synthesis

Uses

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death[1].

in vivo

Milatuzumaba (15 mg/kg/day; i.p.; once every 3 days) significantly increases the survival rate of female SCID mice bearing Jeko cells. And Milatuzumaba has a synergistic effect with Rituximab (HY-P9913) in mouse model^[1].

Animal Model:	Jeko mouse model^[1]
Dosage:	15 mg/kg/day; with or without 15 mg/kg Rituximab
Administration:	Intraperitoneal injection; once every 3 days, starting at day 15 after engraftment
Result:	Resulted the mean survival for the combination treated group of 44.5 days, compared with 33.5 days for Milatuzumaba treated, 28 days for control.

References

[1] Alinari L, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011 Apr 28;117(17):4530-41. DOI:10.1182/blood-2010-08-303354